Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton

Molecular Cancer Therapeutics

Volumn 5, Issue 9, 2006, Pages 2348-2357

  Bijman, Marcel N A ^a   van Nieuw Amerongen, Geerten P ^a   Laurens, Nancy ^a   van Hinsbergh, Victor W M ^a   Boven, Epie ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; F ACTIN; MATRIGEL; PROTEIN CDC42; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TUBULIN; VINBLASTINE;

ANGIOGENESIS; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSKELETON; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME INHIBITION; FLUORESCENCE MICROSCOPY; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROTUBULE; PRIORITY JOURNAL; PROTEIN STRUCTURE; STRESS FIBER; STRUCTURE ANALYSIS; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; CDC42 GTP-BINDING PROTEIN; CISPLATIN; CYTOSKELETON; DOXORUBICIN; ENDOTHELIAL CELLS; EPOTHILONES; HUMANS; MICE; MICROFILAMENTS; MICROTUBULES; NEOVASCULARIZATION, PHYSIOLOGIC; PSEUDOPODIA; RAC1 GTP-BINDING PROTEIN; STRESS FIBERS; TUBULIN MODULATORS; VINBLASTINE;

EID: 33749565180     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0242     Document Type: Article

References (38)

1. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
2. Schimming R, Hunter NR, Mason KA, Miles L. Inhibition of tumor neoangiogenesis and induction of apoptosis as properties of docetaxel (Taxotere). Mund Kiefer Gesichtschir 1999;3:210-2.
3. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61: 3369-72.
4. Vacca A, Ribatti D, Iurlaro M, et al. Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res 2002;11:103-18.
5. Hotchkiss KA, Ashton AW, Mahmood R, et al. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther 2002;1:1191-200.
6. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (Taxol) and docetaxel (Taxotere). Int J Cancer 2003;104:121-9.
7. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol 2004;22:2015-25.
8. Woltering EA, Lewis JM, Maxwell PJ, et al. Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs. Ann Surg 2003;237:790-8.
9. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-43.
10. Vacca A, Iurlaro M, Ribatti D, et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999;94:4143-55.
11. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:1315-24.
12. Soga N, Namba N, McAllister S, et al. Rho family GTPases regulate VEGF-stimulated endothelial cell motility. Exp Cell Res 2001;269:73-87.
13. Nieuw Amerongen GP, Koolwijk P, Versteilen A, van Hinsbergh VW. Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Arterioscler Thromb Vasc Biol 2003;23:211-17.
14. Etienne-Manneville S, Hall A. Cdc42 regulates GSK-3β and adenomatous polyposis coli to control cell polarity. Nature 2003;421:753-6.
15. Etienne-Manneville S, Hall A. Integrin-mediated activation of Cdc42 controls cell polarity in migrating astrocytes through PKCζ. Cell 2001;106: 489-98.
16. Ridley AJ. Rho GTPases and cell migration. J Cell Sci 2001;114: 2713-22.
17. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev Biol 2004;265:23-32.
18. Waterman-Storer CM, Salmon E. Positive feedback interactions between microtubule and actin dynamics during cell motility. Curr Opin Cell Biol 1999;11:61-7.
19. van Hinsbergh VW, Draijer R. Culture and characterization of human endothelial cells. In: Oxford: University Press Shaw A J; 1996. p. 87-110.
20. Verschraagen M, Boven E, Ruijter R, et al. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites. Clin Pharmacol Ther 2003;74:157-69.
21. Brenner DE, Grosh WW, Noone R, et al. Human plasma pharmacokinetics of doxorubicin: comparison of bolus and infusional administration. Cancer Treatment Symposia 1984;3:77-83.
22. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998;16:187-96.
23. Nelson RL, Dyke RW, Root MA. Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treat Rev 1980;7 Suppl 1:17-24.
24. Li D, Williams JI, Pietras RJ. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression. Oncogene 2002;21:2805-14.
25. Hayot C, Farinelle S, De Decker R, et al. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int J Oncol 2002;21: 417-25.
26. Kumar P, Benedict R, Urzua F, et al. Combination treatment significantly enhances the efficacy of antitumor therapy by preferentially targeting angiogenesis. Lab Invest 2005;85:756-67.
27. Ng SS, Figg WD, Sparreboom A. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res 2004;64:821-4.
28. Holwell SE, Hill BT, Bibby MC. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer 2001; 84:290-5.
29. Etienne-Manneville S. Actin and microtubules in cell motility: which one is in control? Traffic 2004;5:470-7.
30. Rosenblum M.D., Shivers RR. "Rings" of F-actin form around the nucleus in cultured human MCF7 adenocarcinoma cells upon exposure to both Taxol and Taxotere. Comp Biochem Physiol C Toxicol Pharmacol 2000; 125:121-31.
31. Pletjushkina OJ, Ivanova OJ, Kaverina IN, Vasiliev JM. Taxol-treated fibroblasts acquire an epithelioid shape and a circular pattern of actin bundles. Exp Cell Res 1994;212:201-8.
32. Wittmann T, Waterman-Storer CM. Cell motility: can Rho GTPases and microtubules point the way? J Cell Sci 2001;114:3795-803.
33. Goncalves A, Braguer D, Kamath K, et al. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci U S A 2001;98:11737-42.
34. Hu YL, Li S, Miao H, et al. Roles of microtubule dynamics and small GTPase Rac in endothelial cell migration and lamellipodium formation under flow. J Vasc Res 2002;39:465-76.
35. Waterman-Storer CM, Worthylake RA, Liu BP, et al. Microtubule growth activates Rac1 to promote lamellipodial protrusion in fibroblasts. Nat Cell Biol 1999;1:45-50.
36. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002;420:629-35.
37. Palazzo AF, Joseph HL, Chen YJ, et al. Cdc42, dynein, and dynactin regulate MTOC reorientation independent of Rho-regulated microtubule stabilization. Curr Biol 2001;11:1536-41.
38. Krendel M, Zenke FT, Bokoch GM. Nucleotide exchange factor GIEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton. Nat Cell Biol 2002;4:294-301.